33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress)
    Meeting Abstract

    Hoimes, C. J.; Flaig, T. W.; Srinivas, S.; Mar, N.; Petrylak, D. P.; O'Donnell, P. H.; Bilen, M. A.; Sasse, C.; Yu, Y.; Birrenkott, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Defining innate immune training potential as a predictor of Bacillus Calmette-Guerin immunotherapy response in nonmuscle-invasive bladder cancer
    Meeting Abstract

    Jiang, S.; Redelman-Sidi, G.; Pietzak, E. J.; Bochner, B. H.; Glickman, M. S.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score
    Meeting Abstract

    Galsky, M. D.; Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Tomita, Y.; Nasroulah, F.; Li, J.; Collette, S.; PeĢrez-Valderrama, B.; Grimm, M. O.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Choueiri, T. K.; Plimack, E. R.; Powles, T.; Voss, M. H.; Gurney, H.; Silverman, R. K.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Hammers, H. J.; McKay, R. R.; Heng, D. Y. C.; Beckermann, K.; Kasturi, V.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): Prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP)
    Meeting Abstract

    Efstathiou, E.; Attard, G.; Lucas, J.; Thomas, S.; Gormley, M.; Aguilar-Bonavides, C.; Flaig, T. W.; Franke, F.; Goodman, O. B.; Oudard, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma
    Meeting Abstract

    Chu, C. E.; De Jesus Escano, M.; Yip, W.; Jiang, S.; Iyer, G.; Al-Ahmadie, H. A.; Goh, A. C.; Dalbagni, G.; Bochner, B. H.; Solit, D. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations
    Meeting Abstract

    Chi, K. N.; Rathkopf, D. E.; Smith, M. R.; Efstathiou, E.; Attard, G.; Olmos, D.; Lee, J. Y.; Small, E. J.; Gomes, A. J.; Roubaud, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results
    Meeting Abstract

    Cella, D.; Motzer, R. J.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J.; Zhang, J.; Simsek, B.; Ivanescu, C.; Choueiri, T. K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mixed methods assessment of providers' needs in the management of advanced renal cell carcinoma
    Meeting Abstract

    Campbell, M. T.; Lazure, P.; Augustyniak, M.; Jaimes, E. A.; Bilen, M. A.; Lemke, E.; Jacobs, G.; McFadden, P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save